Association between aqueous humor and vitreous fluid levels of Th17 cell-related cytokines in patients with proliferative diabetic retinopathy

Masaru Takeuchi \(^1\), Tomohito Sato \(^1\), Yutaka Sakurai \(^1\), Manzo Taguchi \(^1\), Kozo Harimoto \(^1\), Yoko Karasawa \(^1\), Masataka Ito \(^2\)

\(^1\) Department of Ophthalmology, National Defense Medical College, Saitama, Japan, \(^2\) Department of Developmental Anatomy and Regenerative Biology, National Defense Medical College, Saitama, Japan

\* masatake@ndmc.ac.jp

Abstract

Inflammation is known to be involved in the progression of diabetic retinopathy. We have recently reported that vitreous levels of IL-4, IL-17A, IL-22, IL-31, and TNF\(\alpha\) are higher than the respective serum levels in proliferative diabetic retinopathy (PDR) patients, and that vitreous levels of these cytokines are higher in PDR than in other non-inflammatory vitreoretinal diseases or uveitis associated with sarcoidosis. In the present study, we investigated inflammatory cytokines including Th17 cell-related cytokines in aqueous humor samples obtained from eyes with PDR, and analyzed the association between the aqueous humor and vitreous fluid levels of individual cytokines. The study group consisted of 31 consecutive type 2 diabetic patients with PDR who underwent cataract surgery and vitrectomy for vitreous hemorrhage and/or tractional retinal detachment. Undiluted aqueous humor was collected during cataract surgery, and then vitreous fluid was obtained using a 25G vitreous cutter inserted into the mid-vitreous cavity at the beginning of vitrectomy. IL-1\(\beta\), IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-\(\gamma\), soluble CD40 ligand (sCD40L), and TNF\(\alpha\) levels in the aqueous humor and vitreous fluid were measured using a beads-array system. Although IL-17A was detected in the aqueous humor of eyes with PDR and the level correlated with IL-17A level in the vitreous fluid, both percent detectable and level of IL-17A in the aqueous humor were significantly lower than those in the vitreous fluid. Vitreous IL-17A level was related significantly to IL-10, IL-22, and TNF\(\alpha\) levels in aqueous humor as well as in vitreous fluid. On the other hand, aqueous IL-17A level was not related significantly to aqueous or vitreous levels of IL-10, IL-22 or TNF\(\alpha\) level. The present study demonstrated that IL-17A level and detectable rate in the aqueous humor of patients with PDR are markedly lower than those in the vitreous fluid and aqueous IL-17A does not correlate with vitreous levels of other cytokines, and hence should not be used as a surrogate for IL-17A in the vitreous fluid.
Introduction

Diabetic retinopathy (DR) leading to blindness is one of the most severe complications of diabetes. The prevalence of DR and vision-threatening DR in diabetic patients aged 40 years and older in the USA was 28.5% and 4.4%, respectively [1]. In a Japanese study, the incidence of DR in type 2 diabetic patients who had no DR at baseline was 26.6% over 8 years, and the risk of progression to proliferative DR (PDR) in those with mild non-proliferative DR was 15.9% [2].

Chronic inflammation under sustained hyperglycemic condition dysregulates the retinal microvasculature and provokes DR [3, 4]. Neovascularization followed by fibrovascular changes are characteristics of PDR, and result in vitreous hemorrhage or tractional retinal detachment [5]. Various angiogenic factors such as growth factors and inflammatory cytokines have been identified in eyes with PDR, and are implicated in the progression of DR [5–11].

T helper (Th) 17 cells, which preferentially produce interleukin (IL)-17 (also called IL-17A), IL-17F, IL-21, and IL-22 [12], are involved in various inflammatory and autoimmune diseases [13]. IL-17A plays a critical role in the recruitment and activation of immune cells, and induces the production of proinflammatory cytokines by non-immune cells such as fibroblasts, endothelial cells, and epithelial cells [14]. Serum level of IL-17 is elevated in patients with PDR compared with controls [15, 16], and Chernykh et al. [17] report that IL-17A level is also increased in the vitreous fluid in eyes with PDR. We recently reported that vitreous levels of IL-4, IL-17A, IL-22, IL-31, and TNFα in PDR patients were higher than the respective levels in serum, and that vitreous levels of these cytokines were higher in PDR than in idiopathic epiretinal membrane (ERM), macular hole (MH), or uveitis associated with sarcoidosis [18]. On the other hand, IL-17 is also known as an angiogenic factor. Fibroblasts and monocytes stimulated in vitro with IL-17 produce vascular endothelial growth factor (VEGF)-A [19], and IL-17 released in the tumor microenvironment renders tumor resistance to anti-VEGF therapy [20]. In addition, upregulation of VEGF via IL-17 promotes development of microvascular structures in rheumatoid arthritis and tumor growth [21, 22]. In the eye, IL-17 facilitates laser-induced choroidal neovascularization in a VEGF-independent manner [23], and involvement of IL-17 in age-related macular degeneration has been implicated [24–26]. IL-17A expression is also observed in the cornea of eyes infected with herpes simplex virus, which promotes corneal neovascularization via VEGF-A [27]. However, little is currently known about the involvement of IL-17 in the development and progression of DR.

Aqueous humor sample can be collected more easily and repeatedly compared with vitreous fluid. Several studies have shown that IL-6 and VEGF are elevated in the aqueous humor of patients with DR [28–30]. However, IL-17A level in aqueous humor and the relation with other inflammatory cytokines including IL-6 and VEGF in diabetic patients with DR or PDR remain unclear. In the present study, we investigated aqueous humor levels of IL-17A and other inflammatory cytokines, and analyzed the association between aqueous humor and vitreous fluid levels of individual cytokines.

Subjects and methods

Subjects

The study group consisted of 31 consecutive type 2 diabetic patients with PDR who underwent cataract surgery and vitrectomy for vitreous hemorrhage and/or tractional retinal detachment between January 1 and July 31, 2016 in National Defense Medical College. The exclusion criteria were previous vitrectomy, prior intravitreal therapies, trauma, uveitis, and infectious endophthalmitis. The age (mean ± SD) was 56.8 ± 12.4 years (range 36–84), and gender (male/female) ratio was 24/7. Retinal photocoagulation had been performed in 25 eyes (80.6%) before
vitrectomy, and had not been performed in 6 eyes. Vitreous hemorrhage (VH) obscuring fundus findings was observed in 25 of 31 eyes (80.6%). In 8 eyes (25.8%) with or suspected of severe tractional retinal detachment caused by active fibrovascular membrane, intravitreal injection of 1.25 mg/0.05 mL bevacizumab (IVB) was performed 2 or 3 days before vitrectomy to minimize intraoperative hemorrhage.

Ethics statement
The present study was approved by the Institutional Review Board of National Defense Medical College and followed the tenets of the Declaration of Helsinki. Informed consent was acquired from all participants who signed a copy of the Institutional Review Board approved consent form prior to participation.

Sample collection
Approximately 0.2 to 0.5 mL of undiluted aqueous humor was collected during cataract surgery when the anterior chamber was replaced by viscoelastic substance. After cataract surgery, vitreous fluid was obtained using a 25G vitreous cutter inserted into the mid-vitreous cavity at the beginning of vitrectomy before active infusion. Aqueous humor and vitreous samples were transferred into sterile tubes and stored at -70°C until analysis. The vitreous samples were centrifuged to remove cellular components. No complication associated with sampling was observed.

Cytokine measurements
Cytokines in aqueous humor and vitreous fluid samples were measured by the Bio-Plex Pro™ Human Th17 Cytokine Assays® (Bio-Rad Laboratories, Inc. Tokyo, Japan) per manufacturer’s instructions as described previously [18]. The following cytokines were measured: IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ, soluble CD40 ligand (sCD40L), and TNFα. The lower limits of detection obtained from our standard curves, as described in detail previously [18] were 0.27–0.28 pg/ml for IL-1β, 1.3–4.3 pg/ml for IL-4, 0.9–2.6 pg/ml for IL-6, 2.0–3.7 pg/ml for IL-10, 1.5–2.0 pg/ml for IL-17A, 1.8–8.0 pg/ml for IL-17F, 5.0–20.5 pg/ml for IL-21, 4.6–5.0 pg/ml for IL-22, 7.0–26.1 pg/ml for IL-23, 1.2–1.4 pg/ml for IL-25, 2.8–4.8 pg/ml for IL-31, 3.3–7.8 pg/ml for IL-33, 3.2–3.9 pg/ml for IFN-γ, 3.2–7.4 pg/ml for sCD40L, and 0.3–2.4 pg/ml for TNFα.

Statistical analysis
Percent of samples with detectable cytokine in the aqueous humor and vitreous fluid is presented as percent detectable (%), and was compared by Pearson’s chi-squared test. Comparison of cytokine levels between aqueous humor and vitreous fluid was performed using a nonparametric test (Wilcoxon signed-rank test). Cytokines with values below limits of detection were graded as negative and the levels were assigned a numerical value of 0 pg/ml for statistical analysis. Spearman’s correlation coefficient test and multiple regression analysis were used to assess the correlation between cytokine levels in aqueous humor and vitreous fluid. A P value less than 0.05 was considered significant.

Results
Comparison of cytokines in aqueous humor and vitreous fluid
Percent detectable and levels of cytokines in the aqueous humor and vitreous fluid collected from 31 eyes with PDR are shown in Table 1. Cytokines with percent detectable higher than 30% either in the aqueous humor or in the vitreous fluids were IL-6, IL-10, IL-17A, IL-17F, IL-
22, IL-25, IL-31, IFN-γ, sCD40L, and TNFα. Among these cytokines, IL-10, IL-17A, IL-22, and TNFα were detected at significantly lower percentage in the aqueous humor than in the vitreous fluid, while IL-17F, IL-25, IL-31, IFN-γ, and sCD40L were detected at significantly (except IL-31, not significant) higher percentage, and IL-6 was detected in 100% of both aqueous humor and vitreous fluid samples. Fig 1 shows the dot plots of levels of cytokines with percent detectable higher than 30% in either the aqueous humor or vitreous fluid. Similar to the percent detectable results, aqueous humor levels of IL-10, IL-17A, IL-22, and TNFα were significantly lower than the respective levels in vitreous fluid, while aqueous levels of IL-17F, IL-25, IFN-γ, and sCD40L were significantly higher than the respective vitreous levels. Aqueous IL-6 level was significantly higher than the vitreous level.

Association of aqueous with vitreous cytokine levels

Fig 2 presents the correlation between aqueous and vitreous levels of IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-25, IFN-γ, sCD40L, and TNFα. A significant correlation was observed in IL-10 and IL-17A levels. Subsequently, we examined the relationship of IL-17A level with other cytokine levels in the aqueous humor and in the vitreous fluid by multiple regression analysis (Table 2). Vitreous IL-17A level was significantly related to vitreous level of IL-6, IL-10, IL-22, or TNFα, while aqueous IL-17A level was related to aqueous level of IL-25 but not with that of IL-10, IL-22, or TNFα.

Relationship between vitreous IL-17A level with other cytokine levels in aqueous humor or between aqueous IL-17A level and other cytokine levels in vitreous fluid

We examined the relationship between vitreous IL-17A level and aqueous levels of various cytokines as well as between aqueous IL-17A level and vitreous cytokine levels (Tables 3 and 4)
Fig 1. Comparison of cytokine levels in aqueous humor and vitreous fluid of patients with proliferative diabetic retinopathy. Levels of (A) IL-6, (B) IL-10, (C) IL-17A, (D) IL-17F, (E) IL-22, (F) IL-25, (G) IL-31, (H) IFN-γ, (I) sCD40L, and (J) TNFα in aqueous humor (AC) and vitreous fluid (Vit) are shown as dot plots. * P < 0.05 by Wilcoxon signed-rank test.

https://doi.org/10.1371/journal.pone.0178230.g001

Fig 2. Association of cytokine levels in aqueous humor and vitreous fluid of patients with proliferative diabetic retinopathy. Correlation of aqueous level (AC, x-axis) vs. vitreous level (Vit, y-axis) for each cytokine was analyzed by Spearman's correlation coefficient test. (A) IL-6: y = 0.45 + 0.08x, R² = 0.039, P = 0.284; (B) IL-10: y = 10.4 + 1.99x, R² = 0.165, P = 0.02; (C) IL-17A: y = 14.9 + 3.27x, R² = 0.287, P = 0.002; (D) IL-17F: y = 3.66 + 0.09x, R² = 0.042, P = 0.269; (E) IL-22: y = 10.8 + 0.03x, R² = 0.0001, P = 0.956; (F) IL-25: y = 0.24 – 0.001x, R² = 0.00001, P = 0.988; (G) IL-31: y = 4.08 – 0.04x, R² = 0.003, P = 0.775; (H) IFN-γ: y = 1.41 – 0.004x, R² = 0.0001, P = 0.9519; (I) sCD40L: y = 1.58 + 0.03x, R² = 0.009, P = 0.617; and (J) TNFα: y = 4.42 + 0.99x, R² = 0.059, P = 0.188.

https://doi.org/10.1371/journal.pone.0178230.g002
by multiple regression analysis. Vitreous IL-17A level was significantly related to aqueous IL-10, IL-22, and TNFα levels in addition to aqueous IL-17A level (Table 3). On the other hand, aqueous IL-17A level was not related to any of the cytokine levels in vitreous fluid (Table 4).

Table 2. Multiple regression analysis of IL-17A level with other cytokine levels in aqueous humor and vitreous fluid of patients with proliferative diabetic retinopathy (PDR).

| Variable | Estimate | 95% CI         | P value |
|----------|----------|----------------|---------|
| IL-17A (Vit)* |          |                |         |
| Adjusted R² = 0.915  |          |                | <0.0001 |
| IL-6 (Vit) | -0.03    | -0.05 – -0.01  | 0.0181  |
| IL-10 (Vit) | -0.80    | -1.56 – -0.04  | 0.0395  |
| IL-17F (Vit) | 1.04     | -0.72 – 2.80   | 0.2335  |
| IL-22 (Vit) | 1.14     | 0.60 – 1.67    | 0.0002  |
| IL-25 (Vit) | 12.6     | -46.8 – 72.0   | 0.6637  |
| IL-31 (Vit) | -0.66    | -1.54 – 0.23   | 0.1366  |
| IFN-γ (Vit) | 1.06     | -12.0 – 14.1   | 0.8676  |
| sCD40L (Vit) | -0.14    | -8.97 – 8.69   | 0.9733  |
| TNFα (Vit) | 6.35     | 4.23 – 8.48    | <0.0001 |

| IL-17A (AC)† |          |                |         |
| Adjusted R² = 0.333  |          |                | 0.0308  |
| IL-6 (AC) | 0.0004   | -0.004 – 0.005 | 0.8661  |
| IL-10 (AC) | -0.88    | -2.02 – 0.26   | 0.1234  |
| IL-17F (AC) | 0.02     | -0.24 – 0.28   | 0.8889  |
| IL-22 (AC) | 0.56     | -0.43 – 1.54   | 0.2532  |
| IL-25 (AC) | -7.21    | -13.4 – -1.03  | 0.0244  |
| IL-31 (AC) | 0.99     | -0.23 – 2.22   | 0.1054  |
| IFN-γ (AC) | 0.71     | -0.33 – 1.74   | 0.1690  |
| sCD40L (AC) | -0.32    | -1.47 – 0.82   | 0.5618  |
| TNFα (AC) | 1.79     | -0.19 – 3.77   | 0.0735  |

CI: confidence intervals.

* Cytokines in vitreous fluid
† cytokines in aqueous humor.

https://doi.org/10.1371/journal.pone.0178230.t002

Table 3. Multiple regression analysis of IL-17A level in vitreous fluid with cytokine levels in aqueous humor of patients with proliferative diabetic retinopathy (PDR).

| Variable | Estimate | 95% CI         | P value |
|----------|----------|----------------|---------|
| IL-17A (Vit)* |          |                |         |
| Adjusted R² = 0.615  |          |                | 0.0004  |
| IL-6 (AC) † | -0.013   | -0.03 – 0.01   | 0.2171  |
| IL-10 (AC) | 12.3     | 6.64 – 17.9    | 0.0002  |
| IL-17A (AC) | 4.59     | 2.48 – 6.71    | 0.0002  |
| IL-17F (AC) | 0.71     | -0.51 – 1.93   | 0.2378  |
| IL-22 (AC) | -8.28    | -13.0 – -3.55  | 0.0016  |
| IL-25 (AC) | 14.4     | -18.2 – 47.0   | 0.3677  |
| IL-31 (AC) | -2.08    | -8.15 – 3.98   | 0.4819  |
| IFN-γ (AC) | 0.91     | -4.14 – 5.95   | 0.7117  |
| sCD40L (AC) | -1.64    | -7.02 – 3.74   | 0.5332  |
| TNFα (AC) | -12.6    | -22.6 – -2.66  | 0.0156  |

CI: confidence intervals.

* Cytokines in vitreous fluid
† cytokines in aqueous humor.

https://doi.org/10.1371/journal.pone.0178230.t003
Table 4. Multiple regression analysis of IL-17A level in aqueous humor with cytokine levels in vitreous fluid of patients with proliferative diabetic retinopathy (PDR).

| Variable | Estimate | 95% CI | P value |
|----------|----------|--------|---------|
| IL-17A (AC) | IL-6 (Vit) | -0.01 | -0.02 – 0.01 | 0.3805 |
|          | IL-10 (Vit) | 0.28 | -0.06 – 0.64 | 0.1214 |
|          | IL-17A (Vit) | -0.03 | -0.22 – 0.16 | 0.7583 |
|          | IL-17F (Vit) | 0.14 | -0.63 – 0.92 | 0.7081 |
|          | IL-22 (Vit) | -0.13 | -0.45 – 0.18 | 0.3892 |
|          | IL-25 (Vit) | 18.7 | -6.75 – 44.1 | 0.1410 |
|          | IL-31 (Vit) | 0.28 | -0.12 – 0.68 | 0.1553 |
|          | IFN-γ (Vit) | -1.93 | -7.50 – 3.64 | 0.4782 |
|          | sCD40L (Vit) | -0.75 | -4.51 – 3.01 | 0.6819 |
|          | TNFa (Vit) | 0.06 | -1.47 – 1.59 | 0.9361 |

CI: confidence intervals.
*Cytokines in aqueous humor
†cytokines in Vitreous fluid.

https://doi.org/10.1371/journal.pone.0178230.t004

**Association of IL-17F level with other cytokine levels in aqueous humor**

On the other hand, IL-17F was the Th17 cell-related cytokine more frequently detected in aqueous humor than in vitreous fluid. Therefore, we examined the correlation between IL-17F level and levels of other cytokines in the aqueous humor. As shown in Fig 3, aqueous IL-17F level correlated significantly with aqueous level of IL-6, IL-25, IL-31, IFN-γ and sCD40L.

Fig 3. Association of IL-17F level with levels of other cytokines in aqueous humor of patients with proliferative diabetic retinopathy. Correlation of aqueous (AC) IL-17F level (x-axis) vs. aqueous levels of other cytokines (y-axis) was analyzed by Spearman’s correlation coefficient test. (A) IL-6: y = 306.1 + 57.7x, R² = 0.938, P < 0.0001; (B) IL-10: y = 1.74 + 0.010x, R² = 0.008, P = 0.6338; (C) IL-17A: y = 2.98 – 0.003x, R² = 0.0002, P = 0.9347; (D) IL-22: y = 1.84 – 0.008x, R² = 0.005, P = 0.6964; (E) IL-25: y = -0.32 + 0.06x, R² = 0.888, P < 0.0001; (F) IL-31: y = -0.82 + 0.30x, R² = 0.920, P < 0.0001; (G) IFN-γ: y = -1.60 + 0.38x, R² = 0.913, P < 0.0001; (H) sCD40L: y = 1.51 + 0.47x, R² = 0.952, P < 0.0001; and (I) TNFa: y = 1.10 + 0.002x, R² = 0.002, P = 0.8076.

https://doi.org/10.1371/journal.pone.0178230.g003
Discussion

Currently, the principal treatments for DR are strict control of blood glucose and blood pressure, and lipid-lowering therapy in addition to local ocular treatment [31, 32]. Although DR progresses mainly in patients with poor glucoregulation, gradual changes in the eye with DR are hardly reflected by systemic laboratory investigations for monitoring treatment efficacy. The progression of DR can be predicted more precisely by examining local factors. Recent accumulating evidence implies the involvement of inflammation in the pathogenesis of DR [3, 4], suggesting that identification of the correlation between inflammatory factors and DR may provide critical clues on the diagnosis, prevention, and treatment of DR. We have previously reported that Th2 and Th17 cell-related cytokines; specifically IL-4, IL-10, IL-17A, IL-22, IL-31 and TNFα, are exclusively elevated in the vitreous fluid of PDR compared with that of ERM, MH, or uveitis associated with sarcoidosis [18]. However, since it is not possible to collect vitreous fluid repeatedly from the same patients with PDR, vitreous fluid is not an appropriate sample for monitoring biomarkers of PDR progression. Therefore, in the present study, we assayed inflammatory cytokines in intraocular fluids to identify those that are frequently detected (more than 30% of samples) in either the aqueous humor or vitreous fluid, and investigated in detail the correlation between aqueous and vitreous levels of these cytokines. We identified 10 cytokines that were frequently detected in the aqueous humor or vitreous fluid of PDR eyes, including IL-10, IL-17A, IL-31 and TNFα, which were found to be elevated in vitreous samples in our previous study [18], and a correlation was observed between aqueous and vitreous levels for IL-10 and IL-17A (Fig 2). Although these findings suggest that IL-17A in aqueous humor is the most suitable cytokine that reflects inflammatory cytokines characteristically elevated in the vitreous of PDR, the percent detectable and the mean level of IL-17A in aqueous humor were distinctly lower than those in vitreous fluid (Table 1). In addition, aqueous IL-17A level was not related to vitreous level of IL-10, IL-17A or TNFα by multiple regression analysis (Table 4), although significant correlation between aqueous IL-17A and aqueous IL-10, and TNFα levels was observed (S1 Fig). It is necessary to consider alternative cytokines or methods that allow monitoring of the progression of DR using the aqueous humor.

Our results showed that in PDR, IL-17A level in aqueous humor correlated with that in vitreous fluid, although the level and percent detection of IL-17A in aqueous humor were lower than those in vitreous fluid. A similar pattern was observed for IL-10 in primary vitreoretinal lymphoma (PVRL). In PVRL, IL-10 in the vitreous fluid is elevated and vitreal IL-10 to IL-6 ratio higher than 1.0 is considered to indicate PVRL rather than non-infectious uveitis [33]. Kuiper et al. [35] measured IL-10 level in the aqueous humor of PVRL patients and found that IL-10 in aqueous humor is much lower than that in vitreous fluid, although there was a significant correlation between aqueous and vitreous IL-10 levels as well as IL-10 to IL-6 ratio [34]. Whether this trend exists with key cytokines in other ocular diseases remains to be examined.

Since vitreous IL-17A level was related to both vitreous and aqueous levels of IL-10, IL-22, and TNFα, it is possible that immune responses mediated by these cytokines are evoked not only in the posterior segment of eyes with PDR and also in the anterior segment. On the other hand, the most frequently detected Th17-related cytokine in the aqueous humor of eyes with PDR was IL-17F, and not IL-17A (Table 1). Furthermore, aqueous IL-17F level correlated with aqueous levels of IL-6, IL-25, IL-31, IFN-γ, and sCD40L, while aqueous IL-17A was not related to aqueous or vitreous level of most cytokines examined (Table 2). Both IL-17A and IL-17F are hallmark cytokines of Th17 cells, but they are also produced by a wide variety of innate immune cells including γδT cells, several subtypes of type 3 innate lymphoid cells (ILC3s), natural killer (NK) cells, NKT cells and neutrophils [35]. IL-17F shares approximately 50% amino acid sequence
homology with IL-17A, and both upregulate the expression of proinflammatory cytokines and chemokines via NF-kB, MAPK and C/EBP activation by binding to IL-17 receptor A (IL-17 RA) and IL-17 RC complex on target cells [36]. Although IL-17A and IL-17F are involved in the development of inflammation in a similar manner, IL-17A binds to IL-17RA with higher affinity while IL-17F has higher affinity to IL-17RC [37]. In addition, the distributions of IL-17RA and IL-17RC in tissues and cells differ; IL-17RA is expressed mainly on immune cells, while IL-17RC is preferentially expressed on nonimmune cells [38]. Since IL-17F is a weaker inducer of proinflammatory cytokines and is produced by a wider range of cell types including epithelial cells compared with IL-17A [36], it is likely that IL-17F independently evokes similar inflammation in the anterior segment of the eye with PDR via distinct immune pathway from that of IL-17A. We are currently undertaking a study to examine whether elevation of IL-17F in the aqueous humor is specific to PDR by comparing with other ocular diseases.

The pathological roles of IL-17 in the development of DR remain unclear. However, previous study has shown that serum level of IL-17 was elevated in type 2 diabetes mellitus patients with poor glucoregulation compared to those with good glucoregulation, and that reduction of HbA1c upon treatment was associated with a significant decrease in serum IL-17 level [39]. In addition, Xu et al. [40] have demonstrated that the ratio of IL-17A^+CD4^+ T cells in peripheral blood mononuclear cells increased in rats with streptozotocin (STZ)-induced type 1 diabetes, and intravitreal injection of anti-IL 23Rp19 antibody, which blocks the IL-23-Th17-IL-17A pathway, improved the blood-retinal barrier function in STZ-treated rats.

Vitreous levels of most cytokines, including IL-17A, in PDR patients were lower in the present study compared with our previous study [18]. A possible explanation for this discrepancy is the difference in sample preparation procedure between the two studies. In the previous study, vitreous samples were not centrifuged to remove cellular and other components, and collected samples were transferred into sterile tubes and stored at -70˚C until analysis. In the present study, vitreous samples were centrifuged after collection, and the supernatants were frozen. Therefore, cytokines present in the vitreous gel or in cells were removed in the present study. The differences between the two studies raise an important point of the need to standardize sample collection, preparation and test methods when comparing results between centers or studies.

In a previous study, we compared the vitreous levels of cytokines between PDR eyes with and without VH, and reported no significant differences between PDR patients with and those without VH both in percent detectable and mean vitreous levels of all the cytokines tested in that study [18]. In the present study, VH was not observed in the patient with the highest vitreous levels of IL-10, IL-17A and TNFα. However, since PDR is commonly associated with VH, it is difficult to remove the bias of VH in a study of consecutive PDR eyes.

Some studies have indicated that vitreous IL-10 level in DR patients is significantly higher than that in patients with ERM or MH [41, 42]. In our previous study also, IL-10 was detected in the vitreous of PDR patients, but not in the vitreous of patients with ERM or MH [18]. The present study demonstrated a significant correlation between aqueous IL-10 level and vitreous IL-10 level. Aqueous level of VEGF has been shown to correlate positively with macular thickness and severity of macular edema, whereas aqueous IL-10 level correlates inversely with severity of macular edema [43]. In the present study also, IL-10 was negatively related to IL-17A in vitreous fluid (Table 2), it is possible that vitreous IL-10 may play an inhibitory role on the development of PDR to counteract the effect of IL-17A.

**Conclusions**

The present study demonstrated that in patients with PDR, IL-17A was detected in the aqueous humor, and correlated significantly with vitreous IL-17A. However, the percent detectable
and mean level of IL-17A in aqueous humor were significantly lower than those in vitreous fluid, and a relationship between IL-17A level and IL-10, IL-22, and TNFα levels was observed in vitreous fluid but not in aqueous humor. Therefore, aqueous humor IL-17A should not be used as a surrogate of vitreous fluid IL-17A as a biomarker for monitoring progression of DR.

Supporting information

S1 Fig. Association of IL-17A level with other cytokine levels in aqueous humor of patients with proliferative diabetic retinopathy. Correlation of aqueous IL-17A level vs. aqueous levels of other cytokines was analyzed by Spearman’s correlation coefficient test. (A) IL-6: $y = 2299 - 19.0x, R^2 = 0.003, P = 0.778$; (B) IL-10: $y = 1.37 + 0.25x, R^2 = 0.133, P = 0.044$; (C) IL-17F: $y = 33.9 - 0.09x, R^2 = 0.0002, P = 0.9347$; (D) IL-22: $y = 0.79 + 0.27x, R^2 = 0.147, P = 0.033$; (E) IL-25: $y = 1.86 - 0.03x, R^2 = 0.007, P = 0.953$; (F) IL-31: $y = 8.97 + 0.09x, R^2 = 0.147, P = 0.033$; (G) IFN-γ: $y = 11.2 - 0.03x, R^2 = 0.147, P = 0.033$; (H) sCD40L: $y = 14.6 - 0.12x, R^2 = 0.002, P = 0.827$; and (I) TNFα: $y = 0.76 + 0.14x, R^2 = 0.262, P = 0.003$.

Author Contributions

Conceptualization: M. Takeuchi.

Data curation: YS KH TS.

Formal analysis: YK TS.

Funding acquisition: M. Takeuchi MI.

Investigation: M. Taguchi.

Methodology: MI.

Project administration: M. Takeuchi YK.

Resources: YS YK.

Software: M. Takeuchi.

Supervision: M. Takeuchi.

Validation: MI.

Visualization: YS YK.

Writing – original draft: M. Takeuchi.

Writing – review & editing: MI.

References

1. Zhang X, Saadidine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010; 304(6):649–56. PubMed Central PMCID: PMCPMC2945293. https://doi.org/10.1001/jama.2010.1111 PMID: 20699456

2. Kawasaki R, Tanaka S, Tanaka S, Yamamoto T, Sone H, Ohashi Y, et al. Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS). Diabetologia. 2011; 54(9):2288–94. https://doi.org/10.1007/s00125-011-2199-0 PMID: 21630126

3. Meleth AD, Agron E, Chan CC, Reed GF, Arora K, Byrnes G, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005; 46(11):4295–301. https://doi.org/10.1167/iovs.04-1057 PMID: 16249511
11. Murugeswar i P, Shukla D, Rajendran A, Kim R, Namperum alsamy P, Muthukk aruppan V. Proinflamm a-

10. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determ ination of vitreous interleukin-1 (IL-1)

9. Neussa M, Fukush i J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleuk in-17 promotes angio-

8. Pickens SR, Volin MV, Mandelin AM 2nd, Kolls JK, Pope RM, Shahrara S. IL-17 contributes to angio-

7. Abu El-Asrar AM, Nawaz M, Kangave D, Mairaj Siddiquel M, Geboes K. Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy. J Diabetes Res; 2013; 2013:539658. PubMedCentral PMC:PMCPMC3647558. https://doi.org/10.1155/2013/539658 PMID: 2367187

6. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011; 30(5):343–58. Epub 2011/06/04. PubMedCentral PMC:PMCPMC3433044. https://doi.org/10.1016/j.preteyeres.2011.05.002 PMID: 21635964

5. Gologorsky D, Thanos A, Vavvas D. Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy. Mediators Inflamm. 2012; 2012:629452. Epub 2012/10/03. PubMedCentral PMC:PMCPMC3457666. https://doi.org/10.1155/2012/629452 PMID: 23028203

4. Abu El Asrar AM, Maimone D, Morse PH, Gregory S, Reder AT. Cytokines in the Vitreous of Patients With Proliferative Diabetic Retinopathy. Am J Ophthalmol. 1992; 114(6):731–6. PMID: 1463043

3. Tang J, Kern TS. Inflammation in Diabetic Retinopathy. PLoS One. 2015; 10(9):e0137358. PubMedCentral PMC:PMCPMC4564282. https://doi.org/10.1371/journal.pone.0137358 PMID: 26352837

2. Chung AS, Wu X, Zhuang G, Ng Hu, Kasman I, Zhang J, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013; 19(9):1114–23. https://doi.org/10.1038/nm.3291 PMID: 23913124

1. Pickens SR, Volin MV, Mandelin AM 2nd, Kolls JK, Pope RM, Shahrara S. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol. 2010; 184(6):3233–41. PubMedCentral PMC:PMCPMC2857761. https://doi.org/10.4049/jimmunol.0903271 PMID: 20173024

10. Abu El-Asrar AM, Nawaz M, Kangave D, Van Damme J, Abu El-Asrar AM, et al. Auto-

9. Numasa ki M, Fukus hi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003; 101(7):2620–7. https://doi.org/10.1182/blood-2002-05-1461 PMID: 12411307

8. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathoge nesis of autoimmune and

7. Abu El-Asrar AM, Nawaz MI, Kangave D, Mairaj Siddiquei M, Geboes K. Angiogenic and vasculogen ic

6. Takeuchi M, Sato T, Tanaka A, Muraoka T, Taguchi M, Sakura i Y, et al. Elevated Levels of Cytokine s

5. Takeuchi M, Sato T, Tanaka A, Muraoka T, Taguchi M, Sakurai Y, et al. Elevated Levels of Cytokines, IL-17, IL-22, and IL-23, in inflamma tory diseases, and therapeutic strategies. Am J Pathol. 2012; 181(1):8–18. https://doi.org/10.1016/j.ajpath.2012.03.044 PMID: 22640807

4. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005, 6(11):1133–41. PubMed Central PMC:PMCPMC4185697

3. Chen H, Ren X, Liao N, Wen F. Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy. J Int Med Res. 2016.

2. CherrykVV, Varvarinsky EV, Smirnov EV, Cherryk DV, Trunov AN. Proliferative and angiogenic factors in the vitreous of patients with proliferative diabetic retinopathy. Indian J Ophthalmol. 2015; 63 (1):33–6. https://doi.org/10.4103/0301-4738.151464 PMID: 25686060

1. CherrykVV, Varvarinsky EV, Smirnov EV, Cherryk DV, Trunov AN. Proliferative and angiogenic factors in the vitreous of patients with proliferative diabetic retinopathy. Indian J Ophthalmol. 2015; 63 (1):33–6. https://doi.org/10.4103/0301-4738.151464 PMID: 25686060

17. CherrykVV, Varvarinsky EV, Smirnov EV, Cherryk DV, Trunov AN. Proliferative and angiogenic factors in the vitreous of patients with proliferative diabetic retinopathy. Indian J Ophthalmol. 2015; 63 (1):33–6. https://doi.org/10.4103/0301-4738.151464 PMID: 25686060

16. Chen H, Ren X, Liao N, Wen F. Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy. J Int Med Res. 2016.

15. Liu S, Lin YU, Liu X. Protective effects of SIRT1 in patients with proliferative diabetic retinopathy via the inhibition of IL-17 expression. Exp Ther Med. 2016; 11(1):257–62. PubMedCentral PMC:PMCPMC1618871. https://doi.org/10.3892/etm.2016.2877 PMID: 26889251

14. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005, 6(11):1133–41. PubMed Central PMC:PMCPMC4185697

13. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. 2012; 181(1):8–18. https://doi.org/10.1016/j.ajpath.2012.03.044 PMID: 22640807

12. Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol. 2013; 2013:968549. Epub 2013 Jul 14. https://doi.org/10.1155/2013/968549 PMID: 23967673

11. Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukkaruppan V. Proinflamm a-

10. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004; 18(12):1450–2. Epub 2004/07/03. https://doi. org/10.1096/fj.03-1476fje PMID: 15231732
23. Hasegawa E, Sonoda KH, Shichita T, Morita R, Sekiya T, Kimura A, et al. IL-23-independent induction of IL-17 from gammaheleltaT cells and innate lymphoid cells promotes experimental intraocular neovascularization. J Immunol. 2013; 190(4):1778–87. Epub 2013/01/16. https://doi.org/10.4049/jimmunol.1202495 PMID: 23319736

24. Liu B, Wei L, Meyerle C, Tuo J, Sen HN, Li Z, et al. Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J Transl Med. 2011; 9:1–12. Epub 2011/07/19. PubMed Central PMCID: PMCPMC3154861.

25. Wei L, Liu B, Tuo J, Shen D, Chen P, Li Z, et al. Hypomethylation of the IL17RC promoter associates with age-related macular degeneration. Cell Rep. 2012; 2(5):1151–8. Epub 2012/11/28. PubMed Central PMCID: PMCPMC3513594. https://doi.org/10.1016/j.celrep.2012.10.013 PMID: 23177625

26. Shin JI, Bayry J. A role for IL-17 in age-related macular degeneration. Nat Rev Immunol. 2013; 13(9):701. https://doi.org/10.1038/nri3459-c1 PMID: 23969738

27. Suryawanshi A, Veiga-Parga T, Reddy PB, Rajasagi NK, Rouse BT. IL-17A differentially regulates corneal vascular endothelial growth factor (VEGF)-A and soluble VEGF receptor 1 expression and promotes corneal angiogenesis after herpes simplex virus infection. J Immunol. 2012; 188(7):3434–46. PubMed Central PMCID: PMCPMC3512615. https://doi.org/10.4049/jimmunol.1200620 PMID: 22379030

28. Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005; 243(1):3–8. Epub 2004/07/20. https://doi.org/10.1007/s00417-004-0950-7 PMID: 15258777

29. Cheung CM, Vania M, Ang M, Chee SP, Li J. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. Mol Vis. 2012; 18:830–7. Epub 2012/04/19. PubMed Central PMCID: PMCPMC3327438. PMID: 22511846

30. Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013; 19:1734–46. Epub 2013/08/08. PubMed Central PMCID: PMCPMC3733907. PMID: 23922491

31. Group TASSGaAES. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. N Engl J Med. 2010; 363(3):233–44. https://doi.org/10.1056/NEJMoa1001288 PMID: 20587587

32. Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014;(11):CD011234. https://doi.org/10.1002/14651858.CD011234.pub2 PMID: 25420029

33. Wolf LA, Reed GF, Buggaghe RR, Nussenblatt RB, Chan CC. Vitreous cytokine levels. Ophthalmology. 2003; 110(8):1671–2. Epub 2003/08/15. https://doi.org/10.1016/S0161-6420(03)00811-X PMID: 12917196

34. Kuiper J, ten Dam-van Loon N, Domanian A, Schellekens P, Nierkens S, Radstake T, et al. Correlation between measurement of IL-10 and IL-6 in paired aqueous humour and vitreous fluid in primary vitreoretinal lymphoma. Acta Ophthalmol (Copenh). 2015; 93(8):e880–e1.

35. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010; 10(7):479–89. https://doi.org/10.1038/nri2800 PMID: 20559326

36. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011; 34(2):149–62. https://doi.org/10.1016/j.immuni.2011.02.012 PMID: 21349428

37. Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K, et al. Identification of the IL-17 Receptor Related Molecule IL-17RC as the Receptor for IL-17F. J Immunol. 2007; 179(8):5462–73.

38. Ishigame H, Kakuta S, Nagai T, Kodoki M, Nambu A, Komiyama Y, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity. 2009; 30(1):108–19. https://doi.org/10.1016/j.immuni.2008.11.009 PMID: 19144317

39. Sumarac-Dumanovic M, Jeremic D, Pantovic A, Janjetovic K, Stamenkovic-Pejkovic D, Cvijovic G, et al. Therapeutic improvement of glucoregulation in newly diagnosed type 2 diabetes patients is associated with a reduction of IL-17 levels. Immunobiology. 2013; 218(8):1113–8. https://doi.org/10.1016/j.imbio.2013.03.002 PMID: 23623393

40. Xu H, Cai M, Zhang X. Effect of the blockade of the IL-23-Th17-IL-17A pathway on streptozotocin-induced diabetic retinopathy in rats. Graefes Arch Clin Exp Ophthalmol. 2015; 253(9):1485–92. Epub 2014/11/06. https://doi.org/10.1007/s00417-014-2842-9 PMID: 25371107

41. Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol. 2011; 55(3):556–63. Epub 2011/05/04. https://doi.org/10.1007/s10384-011-0004-8 PMID: 21538001

42. Bromberg-White JL, Glazer L, Downer R, Forge K, Boguslawski E, Duesbery NS. Identification of VEGF-Independent Cytokines in Proliferative Diabetic Retinopathy Vitreous. Invest Ophthalmol Vis Sci. 2013; 54(10):6472–80. https://doi.org/10.1167/iovs.13-12518 PMID: 24003089
43. Dong N, Xu B, Chu L, Tang X. Study of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema. PLoS One. 2015; 10(4):e0125329. PubMed Central PMCID: PMCPMC4414516. https://doi.org/10.1371/journal.pone.0125329 PMID: 25923230